Sandhu, S;
Moore, CM;
Chiong, E;
Beltran, H;
Bristow, RG;
Williams, SG;
(2021)
Prostate cancer.
The Lancet
, 398
(10305)
pp. 1075-1090.
10.1016/S0140-6736(21)00950-8.
Preview |
Text
Moore_Prostate Cancer - Lancet 2020_Tracked241120.pdf - Accepted Version Download (409kB) | Preview |
Abstract
The management of prostate cancer continues to evolve rapidly, with substantial advances being made in understanding the genomic landscape and biology underpinning both primary and metastatic prostate cancer. Similarly, the emergence of more sensitive imaging methods has improved diagnostic and staging accuracy and refined surveillance strategies. These advances have introduced personalised therapeutics to clinical practice, with treatments targeting genomic alterations in DNA repair pathways now clinically validated. An important shift in the therapeutic framework for metastatic disease has taken place, with metastatic-directed therapies being evaluated for oligometastatic disease, aggressive management of the primary lesion shown to benefit patients with low-volume metastatic disease, and with several novel androgen pathway inhibitors significantly improving survival when used as a first-line therapy for metastatic disease. Research into the molecular characterisation of localised, recurrent, and progressive disease will undoubtedly have an impact on clinical management. Similarly, emerging research into novel therapeutics, such as targeted radioisotopes and immunotherapy, holds much promise for improving the lives of patients with prostate cancer.
| Type: | Article |
|---|---|
| Title: | Prostate cancer |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/S0140-6736(21)00950-8 |
| Publisher version: | https://doi.org/10.1016/S0140-6736(21)00950-8 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, PHASE-III TRIAL, MITOXANTRONE PLUS PREDNISONE, ANDROGEN DEPRIVATION THERAPY, LONG-TERM SURVIVAL, DOUBLE-BLIND, RADICAL PROSTATECTOMY, ADJUVANT RADIOTHERAPY, ABIRATERONE ACETATE, OPEN-LABEL, ACTIVE SURVEILLANCE |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Surgery and Interventional Sci UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Surgery and Interventional Sci > Department of Targeted Intervention |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10137336 |
Archive Staff Only
 |
View Item |
